Deuterium-focused d-CDMO for Deuterated Drug Programs

A deuterium CDMO connects isotope strategy, deuterated API development, analytical control, process scale-up, CMC support and manufacturing within one phase-appropriate program.

Molecule-specific strategy

Start with the program hypothesis and deuteration site

Clearsynth begins with a confidential review of the molecular objective, proposed deuteration sites, metabolic soft spots, potential hydrogen-deuterium exchange, scrambling or back-exchange risks, and the evidence needed at the current stage. The result is a practical feasibility plan rather than a one-size-fits-all route.

Laboratory scientist evaluating a deuterated molecule development program

Isotope incorporation

Select chemistry for isotope efficiency, scale and supply

Route scouting compares incorporation options against positional selectivity, isotopic outcome, chemical yield, safety, raw-material availability, cost, process robustness and transfer potential.

De novo labelled synthesis

Build the target from isotopically labelled starting materials when positional control and route logic support the program objective.

Hydrogen-deuterium exchange

Evaluate exchange chemistry where site selectivity, enrichment, substrate stability and the risk of later back-exchange can be controlled.

Catalytic incorporation

Assess catalytic isotope incorporation for selectivity, catalyst compatibility, reproducibility, raw-material efficiency and scalable operation.

Process development

Optimize reaction conditions, work-up, crystallization, isolation and drying to connect chemical performance with isotope retention.

Process safety and scale transfer

Define safety information, equipment fit, critical parameters and a transfer package for controlled scale progression.

Manufacturing continuity

Plan starting materials, scale, release activities, validation readiness and supply continuity for clinical and commercial needs.

Analytical control

Measure both chemical quality and isotopic quality

A deuterated molecule requires controls that distinguish conventional chemical purity from the location and distribution of isotope incorporation. Methods and specifications are selected for the molecule, route, risks and program phase.

Isotopic-purity understanding

Isotopic enrichment and residual protium assessment
Isotopologue distribution, isotope position and scrambling evaluation
Back-exchange risk during reaction, work-up, isolation, drying, storage and analysis

Characterization and release support

NMR, LC-MS, chromatography and complementary methods
Identity, chemical purity, isotope incorporation and process-impurity assessment
Phase-appropriate specifications, method development, stability, release testing and documentation

Program journey

From confidential assessment through supply

Assess

Review target, hypothesis, isotope objective, stage, market and known risks under confidential governance.

Feasibility

Compare sites, incorporation routes, enrichment potential, analytics, raw materials and scalability.

Develop

Optimize chemistry, isolation, solid form, methods, impurity controls and isotope retention.

Scale up

Confirm safety, critical parameters, equipment fit, reproducibility and phase-appropriate controls.

Transfer

Build the technology-transfer package, risk register, CMC inputs and validation plan.

Supply

Coordinate clinical-stage supply, release, change management and commercial continuity.

Program governance

Technical work with accountable coordination

Confidential governance

Defined information flows, responsibilities and decision paths protect the program while keeping the right specialists involved.

Risks and milestones

A living risk register connects technical unknowns, mitigations, deliverables, stage gates and agreed milestones.

CMC and GMP readiness

Phase-appropriate documentation, specification strategy, validation planning and technology transfer support later-stage execution.

Explore stable-isotope services Explore analytical capabilities Discuss custom synthesis View standards and research chemicals See API manufacturing capabilities

Technical FAQ

Deuterium CDMO questions

What does a d-CDMO do?

A deuterium-focused contract development and manufacturing organization supports deuteration strategy, isotope incorporation, process and analytical development, scale-up, CMC activities, technology transfer and supply for deuterated molecules.

How are deuteration sites selected?

Site selection considers the program hypothesis, molecular structure, metabolic soft spots, exchange liability, synthetic accessibility, positional selectivity, analytical measurability, isotope retention and the intended product profile.

Which isotope-incorporation routes can be evaluated?

Options can include de novo synthesis from labelled inputs, hydrogen-deuterium exchange and catalytic incorporation. The selected route balances isotopic efficiency, selectivity, chemical yield, safety, scale, cost and raw-material availability.

How are enrichment and residual protium measured?

NMR, LC-MS, chromatography and complementary methods can characterize isotope position, isotopic enrichment, residual protium, isotopologue distribution and chemical purity. The method set is molecule- and phase-specific.

How is back-exchange controlled?

Back-exchange control begins by identifying exchange-prone positions and conditions. Process, work-up, crystallization, drying, storage, sampling and analytical conditions are then evaluated to reduce unintended isotope loss.

Which development stages are supported?

Clearsynth can support confidential assessment, feasibility, process and analytical development, scale-up, transfer, GMP readiness, validation planning, clinical-stage supply and commercial continuity.

What should a deuterated molecule enquiry include?

Provide the molecular structure, program hypothesis, desired deuteration site or isotope objective, program stage, intended market, target scale, known exchange risks, analytical and documentation needs, available route information and timeline.

Reviewed by Clearsynth Technical Team · Updated August 2026

Start a confidential deuterated molecule assessment

Share the molecule, program stage, intended market, target scale, isotope objective, analytical and documentation requirements, and timeline.

Contact the d-CDMO team